Table 4.
Second-line treatments.
| National population1)(n=811) | Regional population1)(n=127) | |||
|---|---|---|---|---|
| n (%) | Time to second-line (months)Mean (median); (95% CI for mean) | n (%) | Time to second-line (months)Mean (median); (95% CI for mean) | |
| First-line: Surgery | N=460 | N=83 | ||
| Second-line treatment | ||||
| SSA2) | 212 (46.1%) | 5.7 (1.3)(4.1-7.3) | 51 (61.4%) | 1.6 (0.5)(0.6-2.6) |
| IFN-alpha | 28 (6.1%) | 3.4 (3.2)(2.8-4.0) | n<5 | n<5 |
| Chemotherapy | 19 (4.1%) | 3.3 (2.3)(1.8-4.8) | n<5 | n<5 |
| Locoregional | 8 (1.7%) | 4.9 (3.9)(2.5-7.4) | 6 (7.2%) | 5.8 (5.7)(2.8-8.8) |
| Other | 7 (1.5%) | n/a | n<5 | n/a |
| No second-line treatment | 186 (40.0%) | n/a | 22 (26.5%) | n/a |
| First-line: SSA2) | N=201 | N=36 | ||
| Second-line treatment | ||||
| Surgery | 105 (52.2%) | 2.1 (1.5)(1.6-2.6) | 27 (75.0%) | 1.5 (1.1)(1.0-1.9) |
| IFN-alpha | 23 (11.4%) | 5.4 (1.8)(1.6-9.3) | n<5 | n<5 |
| Chemotherapy | 11 (5.5%) | 5.4 (2.5)(0.0-12.0) | n<5 | n<5 |
| Other | 8 (4.0%) | n/a | n<5 | n/a |
| No second-line treatment | 54 (26.9%) | n/a | 6 (16.7%) | n/a |
CI: confidence interval; IFN: interferon; SSA: somatostatin analogues.
Footnotes:
1) The Regional population is a subgroup of the National population; hence, the National population and the Regional population should not be compared.
2) Perioperative use of SSA may not have been captured to a full extent, if this was administered by health care personnel (and not purchased by the patient via a prescription).